2024 Progress Report
Innovations in Re-Using Data

Dear Friends,

As I reflect on the incredible progress our field has made with sharing clinical research data, I am struck by how it is increasingly becoming a routine part of science. The growing number of pharmaceutical companies, non-profit and academic institutions that make their clinical trial data available on the Vivli platform alone signal that, more and more, data sharing is “business as usual.” Where the true innovation now lies is in the re-use of that data.

In fact, this year it feels as though we have reached a tipping point. Across numerous diseases, findings from studies that reuse clinical trial data from the Vivli platform and beyond are revealing new treatment approaches and propelling further investigation into novel areas—and living up to the promise of maximizing the value of clinical trial data in oncology, diabetes, HIV/AIDs, infectious disease just to name a few. We have spotlighted just a handful in this report. With the vast amount of clinical trial data now at the fingertips of researchers worldwide, I am confident that we will see scientific breakthroughs accelerate in the coming years. And, as we explored at our 2024 Annual Meeting, if we are smart in how we leverage opportunities in the European Health Data Space and with AI, those possibilities could be limitless.

As always, I thank our members, researchers, advisors and funders–and in particular our newest institutional members DNDi, Brown University and UCLA, and our corporate members Astellas and ONO Pharma who joined Vivli this year—for their support and collaboration in making this all happen. Together, we are transforming the landscape of clinical research data sharing and driving forward discoveries that change lives—here’s to an even more impactful year ahead.  Happy holidays!

 

Rebecca LiREBECCA LI,

PhD, CEO, VIVLI

2024 Researcher Spotlight

Rheumatoid Arthritis Read more
Close
Dr. Kaoru Takase-Minegishi and colleagues undertook a meta-analysis using data from 28 randomized controlled trials, including previously unpublished data that is available on the Vivli platform, to understand how the serological status of people diagnosed with rheumatoid arthritis affects treatment responses to biological disease-modifying anti-rheumatic drugs.
Heart failure Read more
Close
Lower respiratory tract infections are common among elderly patients with heart failure. Using previously unpublished data only available on the Vivli platform, Dr. João Pedro Ferreira examined whether empagliflozin use could reduce the incidence of respiratory infections and thus reduce hospitalization in patients with heart failure.
Cancer Read more
Close
Dr. Ashley Hopkins used individual patient-level data available on the Vivli platform to assesses whether the efficacy of atezolizumab in patients with advanced non small-cell lung cancer is affected by being taken in conjunction with other medications routinely prescribed during cancer treatment.
Type 2 Diabetes Read more
Close
Dr. João Sérgio Neves combined the results of clinical trials for two different drugs that reduce the risk of cardiovascular events in patients with Type 2 Diabetes. His analysis indicates that treating patients with the two drugs together could offer even greater cardiovascular protection.

2024 Revenue and Expenses

 

REVENUE

EXPENSES